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Introduction. AIDA is an interactive educational diabetes simulator available on the Internet without charge since 1996 (accessible
at: http://www.2aida.org/). Since the program’s original release, users have developed new requirements, with new operating
systems coming into use and more complex insulin management regimens being adopted. The current work has aimed to design a
comprehensive diabetes simulation system from both a clinical and information technology perspective. Methods. A collaborative
development is taking place with a new generic model of subcutaneous insulin absorption, permitting the simulation of rapidly-
acting and very long-acting insulin analogues, as well as insulin injections larger than 40 units. This novel, physiological insulin
absorption model has been incorporated into AIDA v4. Technical work has also been undertaken to install and operate the AIDA
software within a DOSBox emulator, to ensure compatibility with Windows XP, Vista and 7 operating systems as well as Apple
Macintosh computers running Parallels PC emulation software. Results. Plasma insulin simulations are demonstrated following
subcutaneous injections of a rapidly-acting insulin analogue, a short-acting insulin preparation, intermediate-acting insulin, and
a very long-acting insulin analogue for injected insulin doses up to 60 units of insulin. Discussion. The current work extends the
useful life of the existing AIDA v4 program.
1. Introduction
Interest in the use of information technology (IT) in diabetes
care is increasing [1, 2]. The rationale underlying this inte-
rest is the hope that computers may provide a way of imp-
roving the therapy offered to diabetic patients—permitting
more patients to be managed more intensively—in line
with the experience of the Diabetes Control and Com-
plications Trial (DCCT) [3]. However, in addition to the
landmark DCCT study [3], there have been other ran-
domised controlled trials that have highlighted the potential
benefits of a more flexible approach to diabetes care. The
DAFNE (dose adjustment for normal eating) approach has
been pioneered in Dusseldorf [4] and since the trialled
in Bucharest [5] and elsewhere [6], as well as more
recently in the UK [7]. This has shown that a structured
training course designed to maintain blood glucose (BG)
control while enabling dietary freedom—teaching diabetes
self-management skills to patients with insulin-dependent
(type 1) diabetes mellitus—can be effective in improving
metabolic control [4–7]. The hypothesis underlying this
approach is that more comprehensive teaching may lead
to attainment of the practical goals achieved in the DCCT.
Furthermore, the DAFNE educational model, which focuses
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on teaching patients the skills to self-adjust insulin dosages
for carbohydrate intake, seems also to be associated with an
improved sense of self-efficacy and treatment satisfaction [8].
The working hypothesis underlying the AIDA interactive
educational diabetes simulation approach is that there are
not enough diabetes educators to provide the sort of inten-
sive insulin therapy offered in the DCCT, and even DAFNE-
style structured teaching sessions can be workforce-intensive
and time-consuming. Therefore, perhaps computer-assisted
learning tools may be able to help in the transfer of
knowledge from health-care professionals to patients [9],
particularly if there becomes a need to offer repeat education
to people with diabetes over a longer period of time.
There are many different aspects to diabetes education;
however, learning facts is only one of these [10]. The ability
to gain experience is also of great importance. It is well
recognised that it is not ideal for patients to learn about
diabetes control solely from real-life experiences because of
the long time frames involved, aside from the possible very
real dangers of hypo- or hyper-glycemia [11]. For this reason,
it has been suggested that an interactive simulation of a
diabetic patient might offer one solution [12].
1.1. AIDA Background. AIDA is a freeware computer pro-
gram that permits the interactive simulation of plasma
insulin and BG profiles for demonstration, teaching, self-
learning, and research purposes. It has been made available
since March/April 1996, without charge, on the World Wide
Web as a noncommercial contribution to continuing diabetes
education. In the 14+ years since its original Internet launch,
over two million visits have been logged to the AIDA Web
pages at http://www.2aida.org/ and http://www.2aida.net/
and over 345,000 copies of the program have been down-
loaded, gratis (Figures 1(a) and 1(b)). Further copies have
been made available, in the past, on diskette by the system
developers [13–17] and from the British Diabetic Associa-
tion, London, UK [18].
When AIDA is run, a dialog box opens and asks the
user to select the status and individual characteristics of
the subject for simulation, including body weight and
main metabolic indices, such as renal threshold of glucose,
creatinine clearance, and peripheral and hepatic insulin
sensitivities (Figure 2(a)). These parameters serve to specify
patients with different degrees of insulin resistance and
various degrees of glycaemic impairment.
Once all the fields are set and new values are saved,
the simulation can be run. Simulation results are presented
in a graphical format (Figure 2(b)), showing blood glucose
and plasma insulin concentrations. Users can specify nearly
unlimited numbers of virtual diabetic patients and test how
different types of treatments, doses and dosing regimens, and
even lifestyle (dietary) changes affect the daily BG profile
(Figure 2(c)). If a simulated regimen is found unable to keep
glycaemia within desired limits, users can experiment with
alternative management regimens to try and improve the
daily BG pattern [19].
An estimate of medium-term BG control which will be
familiar to patients/software users is provided by the AIDA
program via the glycosylated haemoglobin (HbA1c level)
which is estimated on the basis that if the simulated BG
profile was maintained for approximately 8–12 weeks this
is the expected glycaemic control (HbA1c index) that would
result [20, 21]. People with diabetes, ideally, would be aiming
for an HbA1c of 6.0%–6.5%.
A major benefit of using AIDA is that it offers an
opportunity to try and use the patient’s own data, in
an attempt to improve their understanding of their own
diabetes. The AIDA software and underlying model have
been previously described in detail elsewhere in the literature
[10, 22, 23].
1.2. Rationale for Revising the Current AIDA Program. Based
on the large number of downloads, user comments clearly
demonstrate that the AIDA educational software has so far
stood the test of time [24–26]. Like other software products
more than 14 years after their original launch, however, the
time is ripe to consider potential revisions to the existing
AIDA program. Developments both in the clinical and
computational arena clearly point to the need to revise and
extend the current software. User comments have prompted
the systematic revision of the description and spectrum
of diabetes types, as well as interventions/lifestyle events,
handled by the AIDA model.
From a clinical perspective the existing AIDA v4 software
does not cater for the latest insulin analogue preparations
which have become increasingly used in the therapy of
people with insulin-dependent (type 1) diabetes mellitus.
Furthermore, the existing program is unable to simulate
either non-insulin-dependent (type 2) diabetic patients with
endogenous insulin secretion or management regimens
involving insulin infusions in addition to subcutaneous
boluses of insulin. New insights into the processes involving
carbohydrate metabolism should also appear in an updated
version of the educational simulator in order to fully reflect
the complexity of modern day diabetes therapy.
For instance, in clinical practice the regulation of the
BG concentration is mainly achieved by the action of three
control variables: insulin, meals, and oral hypoglycaemic
agents, but also modified by the effects of other factors, such
as physical exercise and stress. This implies a need to extend
the scope of input variables included in the underlying AIDA
model.
There are also a number of technical issues to be resolved
about the current software. The AIDA program, being DOS-
based, is now becoming somewhat dated, and there can be
issues about making use of the AIDA v4.3a downloadable
software under the Microsoft Windows XP, Windows Vista,
and Windows 7 operating systems. Furthermore, it is nec-
essary to respond to some technical requests of AIDA users
and resolve certain Turbo Pascal display problems that seem
to manifest themselves on the latest notebook computers.
The flexibility and user friendliness of the user interface
could also clearly be improved. The main features of the
current and future planned versions of the AIDA software
are contrasted in Table 1.
It is evident that AIDA should remain a user-friendly
program that implements a novel physiological model of the
glucose-insulin system. This paper aims to present both the
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Figure 1: Number of (a) visits and (b) downloads per month at the two AIDA websites (http://www.2aida.org/ and http://www.2aida.net/)
since March/April 1996 when AIDA first went live on the Internet—up to March/April 2010—just before the web launch of AIDA v4.3b.
Despite the age of the software, there continues to be considerable interest in the program with a large number of site visitors and downloads.
clinical and technical results achieved to date in the current
phase of the revision process.
2. Methods
The first update to the AIDA v4.3a program relies on several
new methods which are related to modelling, programming,
and technical issues. These novel developments will be
overviewed in turn.
2.1. Modelling Methods. The underlying AIDA model con-
sists of glucose and insulin submodels. The glucose submodel
describes the temporal evolution of the concentration of
glucose in the blood stream based on the simulated patient’s
management regimen as well as lifestyle (dietary) infor-
mation. BG levels are controlled by various glucose fluxes
into and out of the blood stream. These fluxes are complex
functions of glucose and insulin levels, some of which vary
according to a diurnal rhythm [23]. The glucose submodel
has not been revised in the first phase of the program’s
revision.
The insulin submodel encapsulates equations according
to which insulin molecules enter the circulation from
subcutaneous depots (insulin absorption) and are dis-
tributed/eliminated. As a first stage to updating the AIDA
simulator, a decision was taken to focus on the appearance of
insulin in the plasma following a subcutaneous injection—
thereby incorporating more novel insulin analogues into the
program. In a survey of 200 users of the AIDA v4 software
this was an often requested “wish list” feature for a new
release of the program [24–26].
Subcutaneous insulin absorption is a complex process
which is affected by many factors including tissue blood
flow, injection site/depth, injected volume, and concen-
tration [27]. Following a subcutaneous injection, soluble
insulin forms a subcutaneous depot, where it is present
in several multimeric, primarily hexameric and dimeric,
forms. The subcutaneous depot is cleared by absorption
4 Journal of Electrical and Computer Engineering
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Figure 2: (a) Data entry screen for AIDA software showing the information stored by the program and used to generate its simulations. It
recounts for “Penelope Vincent”—Case Scenario number 0033 in the AIDA database—that “This young woman, who is very overweight, runs
reasonably high blood sugars during the course of the day. At present she is only injecting herself twice daily with two “shots” of intermediate-acting
insulin. How might you add in a short-acting insulin preparation to her regimen to tighten her glycaemic control? Alternatively, see if you can
decrease her carbohydrate intake—thereby perhaps helping her to lose weight—and at the same time improving her blood glucose control. . ..”
(b) Baseline simulation for “Penelope Vincent” Case Scenario number 0033 in the AIDA database using the data shown in Figure 2(a). On
the lower graph insulin intake (Insulatard) twice per day is shown as white bars with the simulated plasma insulin profile superimposed.
Also shown as brown bars are the carbohydrate intake. On the upper graph the simulated blood glucose profile is shown, with an estimated
glycosylated haemoglobin level (HbA1c) of 9.2%. (c) shows the effect on Penelope Vincent’s blood glucose (BG) profile of adding 5 units of a
short-acting (Actrapid) insulin injection at 6 : 45 am. The baseline simulation from Figure 2(b) is shown as the red curve (for comparison).
As can be seen, the addition of 5 IU of short-acting insulin reduces the BG profile during the day—and leads to an improvement in the
estimated medium-term index of the patient’s simulated glycaemic control with an HbA1cof 8.6% (reduced from 9.2% for the simulation
shown in Figure 2(b)). However, please note that, while this improves Penelope’s BG profile, this adjustment does not correct the high BG
level in the evening.
of dimeric insulin molecules into the vasculature [28].
Although absorption of hexameric insulin has been reported,
it is considered not significant as compared to dimeric
insulin [29, 30].
Various insulin absorption models have been proposed
which vary in their degree of complexity. Virtually all of them
handle short-acting (regular) insulin preparations, while
a few handle intermediate-acting insulin and novel insulin
analogues [28, 31, 32].
The Berger-Rodbard model [33] adopted in AIDA v4.3a
was a simple and flexible tool that enabled the estimation
of plasma insulin levels for various insulin preparations.
However, this model was developed at the end of the 1980s
and thus insulin analogues were not included.
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Table 1: Comparison of features in current release of AIDA v4 dia-
betes simulator (on left) with planned features in future versions of
the software (v4.5) and later (on right). IDDM: insulin-dependent
(type 1) diabetes mellitus. NIDDM: non-insulin-dependent (type
2) diabetes mellitus.
AIDA v4 current version
AIDA v4.5 (and later) future
versions
Model building/structure New features
(i) Interconnected
insulin-glucose submodels
(i) Comprehensive
insulin/glucose model built
from unit processes (diabetes
“lego”-land)
(ii) Empirical models for
insulin/glucose dynamics and
control
(ii) Physiologically based
model of insulin absorption
(generic) and kinetics
(iii) Linear insulin
disposition/elimination
(superposition principle
applies)
(iii) Fewer (only necessary and
realistic) assumptions
(iv) Use of fictive
compartment (“active”
insulin)
(iv) Patient specification with
minimal number of
identifiable parameters
(v) Over parameterisation of
patients (use of
nonidentifiable parameters
such as separate hepatic and
peripheral insulin
sensitivities)
(v) Specification of typical
patient types (insulin sensitive
versus resistant, etc.)
parameterised accordingly
Limitations Overcoming limitations
(i) IDDM only (i) Both IDDM and NIDDM
(ii) No insulin analogues
(ii) Both rapidly acting and
very long-acting insulin
analogues added
(iii) Insulin dose ≤40 units (iii) Insulin dose ≤60 units
(iv) Carbohydrate intake/meal
≤80 g
(iv) Carbohydrate intake/meal
≤120 g
(v) Oral hypoglycaemic drugs
not incorporated
(v) Different types of oral
hypoglycaemic drugs included
(vi) Lifestyle events/effects not
included (stress, physical
activity, menstrual cycle, etc.)
(vi) Lifestyle events (stress,
physical activity, menstrual
cycle, etc.) included
Technical New features
(i) Menu driven data entry
(nongraphical)
(i) Intuitive graphical user
interface
A more comprehensive model, which has focused more
on physiology and pharmacokinetics, has been described
by Mosekilde and colleagues [34]. This approach was later
modified by Trajanoski et al. [35] and Wach et al. [36]
in an attempt to allow for parameter estimation based on
plasma insulin profiles. The model was also extended to
support monomeric insulin analogues. Being more physi-
ologically based, the model proposed by Mosekilde et al.
[34] and modified by Trajanoski and colleagues [35] was
chosen as the basis for the insulin absorption model of
Tarı´n and colleagues [37, 38] and the current collaborative
development work with AIDA v4 [39–41]. The Trajanoski
Table 2: Parameter set derived fromMosekilde et al. [34].
Parameter Value Description
Q/mL2 IU−2 0.13
Chemical
equilibrium
constant
B/min−1 1.3∗10−2
Absorption rate
constant
D/cm2 min−1 0.9∗10−4
Diffusion constant
for soluble insulin in
water at 37◦C
C/IU cm3 0.05
Binding capacity for
insulin in the tissue
T/min 800
Average life time for
insulin in its bound
state
model was extended to deal with the long-acting insulin
analogue glargine, thereby covering the whole range of
insulin preparations currently used in medical therapy. Later
works have subsequently appeared in the literature that also
consider insulin glargine, but where the diffusion process is
neglected or approximated [42–44].
The generic insulin absorption model planned for inclu-
sion in AIDA v4 [37, 38] represents diffusion of insulin
through the subcutaneous depot, transformation between
the different insulin states—hexameric, dimeric, and crystal-
lized (in the case of the insulin glargine)—and absorption
through capillary walls. Due to diffusion, the model is no
longer a set of ordinary differential equations, but partial
differential equations (PDEs) dependent on both time and
space. Since the diffusion process is considered homogeneous
and isotropic, the system of PDEs is unidimensional in space
(distance from the injection site).
The generic model is based on published data from the
literature. As described by Tarı´n and colleagues [37, 38] the
parameters of the absorption model for insulin glargine were
found through an iterative identification process, while the
parameters for the rest of formulations were obtained from
the previous works of Mosekilde et al. [34], Trajanoski et al.
[35], Ho¨fig [45], and Gessler [46].
In the study by Mosekilde et al. [34] the model was
adjusted to fit available experimental data and to determine
the effective diffusion constant D for subcutaneous insulin,
the absorption rate constant B for dimeric insulin, the
equilibrium constant Q between hexameric and dimeric
insulin, the typical binding capacity C for insulin in the
tissue, and the average lifetime T for insulin in its bound state
(not to be confused with the new “bound state” of insulin
glargine). Typical values for insulin injection into the thigh
of a fasting person with type 1 diabetes are summarized in
Table 2.
As reported by Trajanoski et al. [35], due to the model
structure, the formal identification techniques cannot be
adopted for the modified model (i.e., the model is theoret-
ically unidentifiable [47]). Further model simplification like
linearization or aggregation of distributed effects cannot be
performed, since the essential characteristics of the model
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would be lost if linearization was done. On the other hand,
model decomposition is not possible, as it is impossible
to measure insulin with different association states in the
subcutaneous depot. Therefore, a parameter set has been
chosen from published in vivo and in vitro experiments as
shown in Table 3.
(i) Values for the diffusion coefficients of insulin and
insulin analogues published by Moeller et al. [48]
were used (the diffusion constant D was measured in
water or tissue biopsies at 37◦C).
(ii) The absorption rate constant for monomeric insulin
was calculated from the slope of the absorption
curves observed by Kang et al. [47]. According to the
assumptions of Trajanoski et al. [35] during the last
phase of the absorption only dimers are absorbed.
Therefore, for the absorption rate constant Bd for
soluble insulin, the final slope of the absorption curve
of Kang et al. [47] is adopted.
(iii) In the study by Mosekilde et al. [34] it was assumed
that the hexameric-dimeric balance is always near
equilibrium, and a large value was chosen for the
parameter P compared to the absorption rate con-
stant Bd. Since even large changes of P do not alter
the results significantly, in the study by Trajanoski et
al. [35] the same value was used.
(iv) For the distribution-elimination model for solu-
ble insulin, parameters reported by Kraegen and
Chisholm [49] were used for the calculations (Ks and
V p).
(v) The plasma elimination rate constant Km for
monomeric analogues was taken from the study by
Robertson et al. [50].
In the studies by Ho¨fig [45] and Gessler [46] the param-
eter Q was modified in order to mimic the absorption curves
measured with different insulin preparations such as rapidly
acting analogues and NPH (see the studies by Kang et al.
[51] and Binder [52]). Readers are referred to the report by
Tarı´n et al. [37] for a detailed description of the mathematics
underlying the generic insulin absorption model.
As the insulin flow into the blood stream is markedly
slower than the elimination of insulin from the plasma,
plasma insulin kinetics are typically described as a single
compartment model representing the blood pool and some
extravascular space from where there is a first-order elim-
ination of insulin. This is the modeling approach that has
been used for the insulin model [33] incorporated within the
existing AIDA v4 program.
2.2. Programming Issues. Themodel of glucose-insulin inter-
action includes a set of differential equations, algebraic
expressions, and parameters which helps to make it more
case-/patient-specific. Model equations are integrated by
separately computing the glucose and insulin submodels.
For simulating type 1 diabetic patients the insulin sub-
model is considered independent of the glucose part of the
model. As none of the parameters associated with the kinetics
Table 3: Parameter set derived from Trajanoski et al. [35].
Parameter Value Description
Q/mL2 IU−2 76
Chemical
equilibrium
constant
Bd/min−1 1.18∗10−2
Absorption rate
constant for dimeric
insulin
Bm/min−1 1.22∗10−2
Absorption rate
constant for
monomeric insulin
P/min−1 0.5 Rate constant
D/cm2 min−1 8.4∗10−5
Diffusion constant
for soluble insulin
Dm/cm2 min−1 1.66∗10−4
Diffusion constant
for monomeric
insulin analogues
KS/min−1 0.09
Plasma insulin
elimination rate
Vp/l 12
Volume of plasma
insulin
compartment
KS/min−1 55
Plasma insulin
elimination rate
constant for
monomeric insulin
analogues
are assumed to be patient-specific, the insulin concentrations
can be precomputed for any possible insulin delivery and
stored prior to use by AIDA. Insulin levels resulting from
any particular insulin regimen are computed by summing up
the precomputed individual contributions corresponding to
the preparations and doses as used in the particular insulin
regimen.
This technique allows the glucose subsystem exhibiting
slower dynamics to be simulated with a 15-minute step size.
It is noted that integrating insulin equations in real time
would require a much smaller step size (less than 1 minute)
due to the short halftime (about 5 minutes) of insulin in the
plasma.
Simulations start with a BG level of 100mg/dL
(5.6mmol/L). Insulin and glycaemic responses are simulated
for 48 hours, and the results of the second day’s simulation
are displayed as the steady state response to the current
therapy.
2.3. Precomputing Insulin Levels. Although insulin levels
corresponding to different types and doses of subcutaneous
insulin preparations need to be determined only once,
these calculations are still time-consuming because of the
complexity of the generic insulin absorption model. As
the coupled PDEs have no closed solution, integration
should be done numerically. It is considered that insulin
after the injection forms a spherical volume in the adipose
tissue and starts to diffuse out symmetrically. Hence, a
numerical implementation has been carried out by means
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Injected volume
fi
fi+1
Vi+1
Ci+1
∆Ci+1/∆t = (1/Vi+1)( fi − fi+1)
Shell boundaries
Figure 3: Injected volume with shells. Diffusion takes place over
shell boundaries, that is, the surface of the shells, and it is
approximated by the balance of insulin flows entering and leaving
the shell (c: concentration; f : insulin flow; V : volume). The flows
are computed according to the first Fick’s law.
of a spatial discretisation consisting of spherical shells with
equal volume, based on the work of Trajanoski et al. [35].
In this solution, an approximation of Fick’s diffusion law
as a balance of flows at each discrete shell is carried out
(Figure 3 [35]).
Initial conditions are provided by the amount (dose) and
type of the injected insulin. For rapidly acting, short-acting,
and intermediate-acting insulin, it is considered that all the
insulin is in the inner shell in chemical equilibrium between
hexameric and dimeric forms. The volume of the inner
shell corresponds to the injected volume. For the outermost
spherical shell it is considered that the insulin concentration
is null outside the considered spherical depot.
It was demonstrated by Tarı´n et al. [38] that a fixed
number of fifteen shells, as considered by Trajanoski et al.
[35], is not sufficient for all insulin types and doses. Thus, a
varying number of shells is considered here depending on the
dose and type of insulin. To calculate the required number of
shells, the absorbed insulin flow is computed in two different
ways that become equivalent for a large enough spherical
depot (Figure 4):
(a) absorbed insulin flow at a given time t is the
collection of insulin absorption flows from each
spherical shell;
(b) absorbed insulin flow at a given time t is the dec-
rement of total insulin in the spherical depot per unit
time.
In the first case (a), if the insulin concentration outside
the considered spherical depot is significant, the computed
value will underestimate the actual insulin absorption flow,
since this insulin will be neglected. However, in the second
case (b), the insulin concentration will be considered as
absorbed, yielding an overestimation. Profiles computed by
each of the methods will converge as the number of shells
is increased, and thus the radius of the spherical depot
increases. As computational time will increase with the
number of shells considered, the solution is accepted as a
compromise between efficiency and precision. The number
of shells is considered adequate when the area under the
curve of the calculated absorption profile (i.e., the sum of
absorption flows from each shell), computed as described in
item (a) above, and the injected dose, differ by less than 1%.
One percent can be considered adequate given that
these losses only occur for small doses that are hardly ever
administered. This represents a good compromise between
speed and precision.
Figure 5 shows the number of shells required for each
insulin type, and doses ranging from 1 to 60 IU, with a
concentration of the preparation of 100mIU/L (U100).
(i) For rapidly-acting insulin analogues, 20 shells is
regarded as enough for doses higher than 20 IU,
but for smaller doses the number of shells required
increases dramatically, reaching 180 shells for 2 IU.
Computation for 1 IU with a 1% target difference was
not possible due to memory constraints.
(ii) For short acting insulin preparations, doses higher
than 10 IU require 10 shells or less; for smaller doses
the number of shells increases up to 120 shells for a
dose of 1 IU.
(iii) For intermediate-acting insulin preparations and
very long-acting insulin analogues, doses higher than
20 IU require only 20 shells, while for doses below
3 IU the number of shells exceeds 100, reaching 180
shells for a dose of 1 IU of insulin.
For smaller doses the injected volume is small, too. This
automatically leads to rather small shell radii. Since the
volume is kept constant, the further from the injection site,
the thinner the shell will be. Furthermore, the smaller the
radii the higher the diffusion speed and the higher the ratio
between shell surface and volume. Therefore, for small injec-
tion doses, the insulin diffuses very quickly from the inner
to the outermost shell and beyond, which leads to the loss if
the number of shells is not sufficient. However as the AIDA
v4 software only handles integer insulin injection doses, less
than 1 IU insulin injection simulations are not required for
the current version of the program. Although for future
paediatric use such issues about fractional insulin injection
dosages may potentially become of greater significance.
Table 4 shows radii of the 15th sphere around the injected
volume for various doses of U100 (100mIU/L) insulin
preparations. As can be seen, the radii are within a reasonable
range with respect to the thickness of the subcutaneous
tissue.
Regarding time discretisation, the Euler method is
applied with a time step of 0.01 minute. The computational
burden to actually calculate insulin absorption flows is
not trivial but does not exceed the capabilities of modern
personal computers either. Calculating the absorption flow
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Figure 4: Two methods of approximation of the absorbed insulin flow: (a) the absorbed insulin flow Iex is obtained as the collection of
absorbed insulin at each shell; (b) the absorbed insulin is obtained as the decrement of total insulin per unit time. If the number of shells is
adequate, the diffusion flow from the outer shell is null and both methods are equivalent.
Table 4: Radius of the 15th sphere for various injected volumes of
U100 (100mIU/L) insulin.
Injected dose/IU Injected volume/mL Radius of 15th sphere/mm
1 0.01 3.4mm
2 0.02 4.2mm
5 0.05 5.8mm
10 0.1 7.3mm
20 0.2 9.1mm
of one 18 IU injection of glargine, for example, needs roughly
three seconds on a 1.4GHz Pentium class PC without any
effort in the implementation. Doing the same on a portable
device like a PocketPC or smart phone, equipped with
a 200MHz StrongArm CPU, will require more patience
but can be done in less than ten seconds especially if a
highly optimized implementation is used. This remains true
for the vast majority of insulin injection doses. It is only
when calculating extremely low doses that much longer
computational times are observed. As can be seen, the
number of required shells may increase dramatically for low
insulin doses (Figure 5).
At low insulin doses computational time can become
excessive, and running the simulations in “real time” may
not be appropriate. For this reason, AIDA v4 relies on
precomputed insulin profiles.
2.4. Technical Issues. There have been some reported display
issues with the existing AIDA v4 software operating under
Windows XP, particularly with the latest laptop/notebook
PCs. Also Microsoft Windows Vista and Windows 7 do not
allow legacy Disk Operating System (DOS) applications
to switch to full-screen display mode, as required by
AIDA v4. Therefore, in order for AIDA to run optimally
under Windows XP—and operate under Windows Vista
and Windows 7—an alternative display approach has been
investigated. Instead of trying to execute AIDA directly
as a standalone application, as has been done previously,
the idea has been developed to run AIDA using a DOS
emulator. This emulator is a Windows application itself that
mimics the behaviour of the 16-bit DOS operating system
for which AIDA was originally designed. The concept is
that AIDA should then in turn run within this emulator,
hidden from the Windows XP/Vista/7 operating systems,
yet in a way that would be transparent to the user. This
approach is similar to amethod adopted previously to permit
AIDA v4 to operate on Apple Macintosh computers, using
SoftWindows or PowerPC emulation software on Apple
Macs (http://www.2aida.org/applemac/) [53]. The approach
has been investigated for notebook and desktop PCs running
Windows XP, Vista, and 7 to prolong the useful “shell life” of
the existing AIDA v4 software and permit people to continue
making good use of the program.
DOSBox is a lightweight DOS emulator that has gained
wide acceptance in the DOS gaming community. It is
published under a General Public Licence (GPL) and can
be used and distributed freely without charge or fee. Packed
with a handy installer, it comes as a 1.5Mb download, which
is acceptable even for users with slow Internet connections.
It is freely available from http://www.dosbox.com/.
Installing and starting DOSBox is a straightforward
process. DOSBox also offers a convenient way to configure
itself. Upon running DOSBox, it scans the directory in which
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Figure 5: A bench test study concerning spatial discretization
reveals that a fixed number of shells is not appropriate for any
insulin class, dosage, or preparation. Accurate simulation results
depend on the insulin preparation and the dose. The number of
shells required for an insulin absorption profile computation with
an area under the curve (AUC) error below 1% is shown. The
time step considered for 2 IU of rapidly acting insulin was reduced
to 0.002 to avoid numerical instabilities. The value for 1 IU could
not be computed due to memory resources limitations (number of
shells greater than 250 are estimated).
it is located for a file called “dosbox.conf.” Within this file,
various settings can be prespecified. Among these are the
keyboard layout, the emulation speed, and all the steps to
be executed automatically right after starting DOSBox. In
this way, DOSBox can be tailored to suit the hardware and
software environments found on the host computer. All
possible settings are documented at the DOSBox website
(http://www.dosbox.com/).
The possibility to configure the keyboard layout is
especially important as AIDA is used internationally. By
exploiting the “autorun” section mechanism in the “dos-
box.conf” file, DOSBox can also be configured to start
emulating AIDA upon invocation. Therefore, usage of the
DOSBox DOS emulator can be implemented in a way that
is entirely transparent to the AIDA user.
Interestingly, the display problems, AIDA v4.3a can show
on some of the latest notebook PCs are not experienced
when AIDA is run within DOSBox. As these problems might
be related to missing UNICODE support of the compiler
with which AIDA was compiled, the solution of this problem
does not come as a surprise as DOSBox emulates the ASCII
environment for which AIDA v4 was compiled.
Installation of a combined AIDA/DOSBox application
can also be streamlined. In order to emulate AIDA, not
all files that the standard DOSBox installer copies to the
host computer are actually needed. As neither special
sound output nor game-relevant hardware support (e.g., for
joysticks) are required, it is sufficient to copy the DOSBox
executable, the “dosbox.conf” file for the host computer, and
the two Simple DirectMedia Layer (SDL) library files which
provide cross-platform multimedia capabilities designed to
offer fast access to the graphics frame buffer.
If the AIDA installer then updates the “dosbox.conf” file
with the path to the AIDA executables and the keyboard
layout autoidentified at install time and lets the created links
in the start menu folder point to the DOSBox executable
instead of the AIDA executable, then AIDA can be used
in a streamlined manner on any Microsoft Windows PC
operating system, including Windows XP, Windows Vista
and Windows 7.
The installer for AIDA has been created with the Nullsoft
Scriptable Install System (NSIS). This is an advanced open
source installation system that can be used for free. NSIS
is especially suited for the AIDA installation as it allows
more complex tasks to be performed than mere file unpack
and copy routines (Figure 6(a)). Instead, via its inherent
script system, it can, for instance, call any operating system
application programming interface (API) functions. In this
way, it is possible to query, for example, the keyboard layout
of the computer on which AIDA is to be installed. Moreover,
NSIS supports several handy script functions to edit text files.
Thus, it can perform all the configurations of the DOSBox
environment. Furthermore, being open source software and
freeware it is very compatible with the AIDA freeware ethos.
The DOSBox/NSIS approach has been extensively trialed,
and a technical update to AIDA (called AIDA v4.3b) has been
developed which provides a “turnkey” streamlined installa-
tion of AIDA v4 incorporating the DOSBox functionality in
a user friendly format for Windows XP, Vista, and 7 users.
The new version of AIDA v4.3b has been released on the
Internet in April 2010. Figure 6 shows AIDA v4.3b operating
in this way successfully under the (b) Windows XP, (c)
Windows Vista, and (d) Windows 7 operating systems.
The AIDA v4 simulator itself comes accompanied by
a second application, called AIDADEMO, which provides
a demonstration of what AIDA can do for users who
are not sure whether to download the full program. The
AIDADEMO guides the user through a series of slides
which explain usage and the theoretical background of the
simulator, thereby pointing out the program’s capabilities
and limitations. As AIDADEMO has originally been created
using a similar development environment to AIDA v4 itself,
it naturally may have similar operating system issues to
the parent AIDA application. However, just as with AIDA,
these issues have been addressed by use of the DOSBox
approach bundled with the NSIS installer. Figure 6(e) shows
a screenshot from the AIDADEMO application demonstrat-
ing for a different person (“Joy Wilson”), a 70 kg insulin-
dependent diabetic patient, the effect of missing the usual
morning insulin injection before breakfast with the profound
hyperglycaemia (raised blood glucose) that is predicted to
occur in the afternoon. The DOSBox/NSIS packaged release
of AIDADEMO is accessible at the AIDAwebsite at the end of
viewing the web-based demo at http://www.2aida.org/demo/
or directly at http://www.2aida.org/aidademo/ (Figure 6(f)).
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Figure 6: Continued.
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Figure 6: (a) shows the Nullsoft Scriptable Install System (NSIS) in operation—which is used to set up and install AIDA v4.3b on Windows
XP, Windows Vista, and Windows 7 PCs, as well as on Apple Macs running PC emulation software. (b) shows AIDA v4.3b operating
successfully within a window on a PC running the Windows XP operating system. The effect of increasing the 6 : 45 am Insulatard insulin
injection dose from 10 IU to 15 IU is shown—with a concomitant reduction in the blood glucose (BG) profile. The resulting estimated HbA1c
is calculated by AIDA v4.3b to be improved at 8.0% (down from 8.6% for the previous simulation from Figure 2(c) which is shown as the red
BG curve for comparison). (c) AIDA v4.3b operating successfully within a window on a PC running the Windows Vista operating system.
The effect of increasing the 6 : 45 am Insulatard insulin injection dose by 5 more units of insulin to 20 IU is shown—with a concomitant
further reduction in the blood glucose (BG) profile. The resulting estimated HbA1cis calculated by AIDA to be further improved at 7.5%.
The previous two simulations from Figures 2(c) and 6(b) are shown as the red BG curves for comparison. A user specifiable normoglycaemic
range is also shown demonstrating the target range that the user might aim for. BG values are shown in units of mg/dL—much used
in North America and other countries around the world. AIDA can present simulation results in both mmol/L and mg/dL. 1mmol/L of
glucose = 18mg/dL. (d) AIDA v4.3b operating within a window on a PC running the Windows 7 operating system. The effect of a change
in the carbohydrate intake has been simulated, with a reduction in the size of the 4pm snack from 20 grams of carbohydrate to 5 grams
of carbohydrate being shown. This change results in a reduction in the estimated HbA1cto 7.3% (from 7.5% for the simulation shown in
Figure 6(c)—the simulation from which is shown as the red blood glucose curve for comparison on this graph). (e) shows a screenshot
from the AIDADEMO application demonstrating for “Joy Wilson,” a 70 kg insulin-dependent diabetic patient, the effect of missing her
usual morning insulin injection before breakfast with the profound hyperglycaemia (raised blood glucose) that is predicted to occur in the
afternoon. (f) shows where the new DOSBox/NSIS packaged release of AIDADEMO is available for freeware download at the AIDA website
from http://www.2aida.org/aidademo/. (g) AIDA v4.3b software operating within a window on an Apple Macintosh computer running the
Parallels Windows emulation software. The original simulation from Figure 2(b) has been used as the baseline for this example and the effect
of reducing each meal and snack by 10 grams of carbohydrate is simulated. As can be seen, this improves the estimated HbA1c from 9.2%
(Figure 2(b)) to 8.3% with a 50 gram per day reduction in carbohydrate intake. (h) A further example of AIDA v4.3b operating within a
window on an Apple Macintosh computer running the Parallels Windows emulation software. The simulation from Figure 6(g) is shown as
a baseline (in red), and the concomitant effect of increasing the 6 : 45 am Insulatard insulin injection by 5 IU from 10 IU to 15 IU is shown
with an improvement in the overall blood glucose profile, with a reduction in estimated HbA1c from 8.3% (Figure 6(g)) to 7.7%.
2.5. Running AIDA v4.3b on Apple Macintosh Computers.
Since the year 2000 the AIDA website has supported the use
of AIDA v4 under SoftWindows and PowerPC emulation
software on Apple Macintosh computers [53], and see
http://www.2aida.org/applemac/. Since the adoption of Intel
microprocessors by Apple in 2006, Windows applications
can be executed even more efficiently on Mac operating
systems OSX. This requires the installation of Windows
on the Mac machine, and the use of Boot Camp (if it
is intended to start the machine under Windows), or a
virtualization application (like Parallels or VMware Fusion).
In the first case, Windows will have access to all the resources
of the Mac machine. In the second case, a virtual Windows
machine will be created, sharing resources with Mac OSX.
Virtualization is based on the creation of virtual hardware
by means of software. Although this will consume more
resources since Mac OSX and Windows will be running at
the same time, it is convenient if the user does not want
to restart the machine every time they need to execute a
Windows application. VMware Fusion and Parallels require
an Intel Mac, a minimum of Mac OSX v10.4.6 Tiger, and
1Gb of RAM. Boot Camp is a built-in function from Mac
OSX v10.5 Leopard. Parallels Desktop 5 and VMware Fusion
3 for Mac OSX v10.6 Snow Leopard both offer compatibility
with Windows 7.
The use of any of the above tools will allow the execution
of AIDA v4.3b on any Intel-based Mac machine. By way of
illustration, the execution of AIDA v4.3b on aMacOSX Tiger
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Figure 7: Plasma insulin simulations following subcutaneous injections of (a) a rapidly acting insulin analogue (such as lispro/Humalog or
aspart/NovoLog), (b) a short-acting (regular) insulin preparation (e.g., Actrapid), intermediate-acting insulin (both (c) Semilente and (d)
NPH types), and (e) a very long-acting insulin analogue (such as glargine/Lantus) for injected insulin doses up to 60 units of insulin.
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Figure 8: Prototype simulation using the superposition principle
to calculate a plasma insulin profile based on exogenous insulin
injections and estimated basal endogenous insulin secretion in a
type 2 diabetic patient who takes 6 units of short-acting (regular)
insulin and 12 units of intermediate-acting (NPH type) insulin
in the morning with a further 4 units of short-acting (regular)
insulin and 8 units of intermediate-acting (NPH type) insulin in the
evening. The estimated basal endogenous insulin secretion is shown
by the light blue (cyan) line—and the overall plasma insulin profile
is superimposed.
machine with Parallels is shown in Figures 6(g) and 6(h).
This approach has been tested on a Macbook Pro and on
an iMac—using Parallels to execute a virtual machine with
Windows XP.
AIDA v4.3b, like AIDA v4.3a before it, is intended for use
on PC platforms, or Apple Macintosh computers running
suitable PC emulation software. A further freeware upgrade,
called AIDA v4.5 (currently under development), is planned
incorporating the generic insulin model into the AIDA
v4 software—allowing the interactive simulation of lispro,
aspart, and glargine insulin analogues.
3. Results
Figure 1 shows the AIDA Website logstats for the number of
visitors and AIDA v4 downloads since the software went on
freeware Internet release—demonstrating the large number
of site visitors and downloads that have taken place.
Figures 2 and 6 show a case study using AIDA v4.3b—
which demonstrates some of the ways in which the software
can be applied as an educational/demonstration/teaching
tool. “Penelope Vincent”—case scenario number 0033 in
the AIDA database—is a young woman, who is overweight
(98 kg) and runs reasonably high blood sugars during the
course of the day. At present she is only injecting herself
twice daily with two “shots” of intermediate-acting insulin.
The AIDA software asks the user “How might you add in
a short-acting insulin preparation to her regimen to tighten
her glycaemic control? Alternatively, see if you can decrease
her carbohydrate intake—thereby perhaps helping her to lose
weight—and at the same time improving her blood glucose
control. . ..” Various examples of ways in which Penelope’s
glycaemic control might be improved are simulated for
educational purposes in Figures 2(c) and 6. The AIDA v4.3b
freeware software is shown running on personal computers
under the Windows XP, Windows Vista and Windows 7
operating systems in a DOSBox environment (Figures 6(b)–
6(d)), as well as under Parallels on Apple Macs (Figures 6(g)
and 6(h)).
Plasma insulin simulations are also demonstrated using
the novel generic model following subcutaneous injections
of a rapidly acting insulin analogue (such as lispro/Humalog
or aspart/NovoLog), a short-acting (regular) insulin prepa-
ration (e.g., Actrapid), intermediate-acting insulin (both
Semilente and NPH types), and a very long-acting insulin
analogue (such as glargine/Lantus) for injected insulin doses
up to 60 units of insulin (Figure 7).
4. Discussion
Interactive simulators offer users the chance to test the
behaviour of the simulated object without risk. Diabetes
simulators can animate an underlying model of glucose
metabolism and may help to train users to manage “virtual
diabetic patients” with the possibility of changing decisions
or starting again in the case of failure.
Numerous models of the human glucoregulatory system
have been reported [22, 54–57] However, these models may
not be so useful for individual patients, their relatives, health-
care professionals, or students without some sort of program
(a “simulator”) to allow easy access to, and interaction
with, the model. A range of interactive simulation programs
of glucose-insulin interaction in diabetes have also been
described in the literature [12, 28, 33, 57–62]. A few notable
simulators have been circulated on diskette for use by select
health-care professional/research users [13–17, 19]. Some
authors [22, 33, 63, 64] have also developed a simulation
program which could be obtained upon request.
However, for the majority of simulation programs [28,
58–61], it would seem that readers have been wholly depen-
dent on the authors’ own descriptions of their prototypes in
research articles, since no versions appear to be available for
general use by others.
With AIDA, the program has been made widely avail-
able, gratis, via the Internet, from its own Websites—
http://www.2aida.org/ and http://www.2aida.net/—as a non-
commercial contribution to continuing diabetes educa-
tion. This has led to a substantial experience with the
program—globally—with over 347,000 downloads of the
software taking place from more than 100 countries
worldwide. Independent reviews of AIDA can be found
on the Web at http://www.mendosa.com/aida.htm and
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http://www.2aida.net/aida/review.htm as well as in a range of
publications [65–69].
The AIDA diabetes simulator provides a user-friendly
way of making use of the AIDA model in an interactive,
intuitive, and freeware manner. It would assist research
into the use of such applications in this area, as well as
possibly benefit the wider diabetes community, were more
such diabetes simulation programs made available for free
on the Internet.
4.1. Future Work. Table 1 shows the directions in which
the AIDA software is intended to be developed. Revisions
will affect the model, coverage of disease types, and the
management and lifestyle events affecting BG levels.
The current hardwired mathematical model will be
replaced by amodular (“lego”-like) design in which unit pro-
cesses are clearly identified and interactions are formulated
in a systematic and formal way. The revised/extended model
aims to be physiologically based using parameters with
values that are reasonable and which permit physiological
interpretation. The insulin absorption model implemented
in the revised diabetes simulator offers a description of what
happens after the subcutaneous injection of different insulin
preparations, including insulin analogues, with realistic
assumptions and a minimal number of model parameters.
Similar revisions of the glucose submodel are anticipated.
In due course it is planned to update AIDA further to
make it possible to simulate glycaemic responses in non-
insulin-dependent (type 2) diabetic patients. The superpo-
sition principle adopted within the AIDA model [23], of
course, could also apply to insulin that has been secreted
by pancreatic beta cells. Such endogenous secretion evolves
over time corresponding to the temporal variations in BG
concentrations. The insulin levels arising from endogenous
insulin sources at any time can be computed as the sum
of effects of all insulin that has been secreted in the
preceding four hours (insulin levels are known to fall nearly
to zero within four hours following a short intravenous
bolus of insulin). For this computation the plasma and
“active” insulin levels in response to a reference constant
rate of insulin infusion delivered to the plasma over a
short time period would be required. In each 15-minute
integration step the average endogenous insulin secretion
would be computed as the response to the average BG level
in that period. The overall effect of endogenous insulin
secretion would be computed by adding together individual
contributions, in a similar way to that done currently with
exogenous insulin injections.
Figure 8 shows a prototype simulation using the super-
position principle to calculate a plasma insulin profile
based on exogenous insulin injections and estimated basal
endogenous insulin secretion in a type 2 diabetes patient.
The patient takes 6 units of short-acting (regular) insulin
and 12 units of intermediate-acting (NPH type) insulin
in the morning with a further 4 units of short-acting
(regular) insulin and 8 units of intermediate-acting (NPH
type) insulin in the evening. The estimated basal endogenous
insulin secretion is shown—and the overall plasma insulin
profile is superimposed.
It is intended to implement a similar facility within AIDA
to provide simulations and a representation for insulin-
treated type 2 diabetic patients.
Further inputs such as carbohydrate intake/meals up
to 120 grams in size as well as different types of oral
hypoglycaemic agents and lifestyle events (stress, physical
activity, menstrual cycle, etc.) will also be added. Finally the
revised AIDA simulator should be easily used via an intuitive
graphical user interface.
5. Conclusion
In this paper the development and freeware Internet launch
of AIDA v4.3b has been described. This incorporates tech-
nical work ensuring the diabetes simulation software, and
a runtime demonstration program, continue to operate
seamlessly under the Windows Vista, Windows 7, and Apple
Macintosh operating systems. Plasma insulin simulations
are demonstrated following subcutaneous injections of a
rapidly acting insulin analogue (such as lispro/Humalog or
aspart/NovoLog) and a very long-acting insulin analogue
(such as glargine/Lantus) for injected insulin doses up to
60 units of insulin. Further work is planned to validate
the generic model of insulin absorption in parallel with its
incorporation into an updated release of the freeware AIDA
software (AIDA v4.5).
5.1. System Availability. AIDA v4.3b is freely available for
download from http://www.2aida.org/. Following comple-
tion of further programming, validation, and bench testing
work, it is expected that a new, improved version of AIDA
(v4.5)—incorporating Humalog/lispro and Lantus/glargine
insulin analogues—will become available at the same website
for freeware download and educational use. Readers who
wish to be automatically informed by email when the new
software is launched are welcome to join the very low volume
AIDA registration/announcement list by sending a blank
email note to subscribe@2aida.org.
Please note that “Penelope Vincent” and “JoyWilson” are
pseudonyms.
Abbreviations
BG: Blood glucose
PC: Personal computer
IU: International units (of insulin).
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